346 related articles for article (PubMed ID: 31225409)
41. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives.
Boggi U; Kauffmann EF; Napoli N; Barreto SG; Besselink MG; Fusai GK; Hackert T; Hilal MA; Marchegiani G; Salvia R; Shrikhande SV; Truty M; Werner J; Wolfgang C; Bannone E; Capretti G; Cattelani A; Coppola A; Cucchetti A; De Sio D; Di Dato A; Di Meo G; Fiorillo C; Gianfaldoni C; Ginesini M; Hidalgo Salinas C; Lai Q; Miccoli M; Montorsi R; Pagnanelli M; Poli A; Ricci C; Sucameli F; Tamburrino D; Viti V; Cameron J; Clavien PA; Asbun HJ;
Updates Surg; 2024 Apr; ():. PubMed ID: 38684573
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer.
Reilley MJ; Shroff R; Varadhachary GR
Indian J Surg; 2015 Oct; 77(5):403-8. PubMed ID: 26722204
[TBL] [Abstract][Full Text] [Related]
43. Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives.
Coppola A; La Vaccara V; Farolfi T; Fiore M; Cammarata R; Ramella S; Coppola R; Caputo D
Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140192
[TBL] [Abstract][Full Text] [Related]
44. Imaging for pancreatic ductal adenocarcinoma.
Horvat N; Ryan DE; LaGratta MD; Shah PM; Do RK
Chin Clin Oncol; 2017 Dec; 6(6):62. PubMed ID: 29307202
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
Tesfaye AA; Philip PA
Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
[TBL] [Abstract][Full Text] [Related]
46. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
47. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
Wo JY; Niemierko A; Ryan DP; Blaszkowsky LS; Clark JW; Kwak EL; Lillemoe KD; Drapek LN; Zhu AX; Allen JN; Faris JE; Murphy JE; Nipp R; Fernandez-Del Castillo C; Ferrone CR; Hong TS
Am J Clin Oncol; 2018 Jul; 41(7):656-661. PubMed ID: 28134673
[TBL] [Abstract][Full Text] [Related]
48. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer.
Nahm CB; Turchini J; Sahni S; Moon E; Itchins M; Arena J; Chou A; Colvin EK; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892879
[TBL] [Abstract][Full Text] [Related]
49. Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors.
Kato H; Horiguchi A; Ito M; Asano Y; Arakawa S
Ann Gastroenterol Surg; 2021 Mar; 5(2):132-151. PubMed ID: 33860134
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant therapy in pancreatic cancer: an emerging strategy.
Bittoni A; Santoni M; Lanese A; Pellei C; Andrikou K; Stefano C
Gastroenterol Res Pract; 2014; 2014():183852. PubMed ID: 25101123
[TBL] [Abstract][Full Text] [Related]
51. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
[TBL] [Abstract][Full Text] [Related]
52. Multimodality management of borderline resectable pancreatic adenocarcinoma.
Prakash LR; Katz MHG
Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
[TBL] [Abstract][Full Text] [Related]
53. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
54. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
[TBL] [Abstract][Full Text] [Related]
55. Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.
Pedrazzoli S
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892599
[TBL] [Abstract][Full Text] [Related]
56. Cutting-edge strategies for borderline resectable pancreatic cancer.
Shinde RS; Bhandare M; Chaudhari V; Shrikhande SV
Ann Gastroenterol Surg; 2019 Jul; 3(4):368-372. PubMed ID: 31346575
[TBL] [Abstract][Full Text] [Related]
57. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
[TBL] [Abstract][Full Text] [Related]
58. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis.
Ratnayake B; Savastyuk AY; Nayar M; Wilson CH; Windsor JA; Roberts K; French JJ; Pandanaboyana S
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32640720
[TBL] [Abstract][Full Text] [Related]
59. Therapy of Locally Advanced and Oligometastatic Pancreatic Adenocarcinoma.
Wahler IL; Damanakis A; Große Hokamp N; Bruns C; Schmidt T
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136425
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials.
Cloyd JM; Heh V; Pawlik TM; Ejaz A; Dillhoff M; Tsung A; Williams T; Abushahin L; Bridges JFP; Santry H
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32326559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
